KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Receivables (2018 - 2026)

Takeda Pharmaceutical has reported Receivables over the past 9 years, most recently at $5.4 billion for Q1 2026.

  • For Q1 2026, Receivables rose 7.02% year-over-year to $5.4 billion; the TTM value through Mar 2026 reached $5.4 billion, up 7.02%, while the annual FY2026 figure was $5.6 billion, 11.32% up from the prior year.
  • Receivables was $5.4 billion for Q1 2026 at Takeda Pharmaceutical, up from $5.0 billion in the prior quarter.
  • Across five years, Receivables topped out at $5.4 billion in Q1 2026 and bottomed at $529.0 million in Q1 2023.
  • The 5-year median for Receivables is $4.9 billion (2024), against an average of $3.3 billion.
  • Year-over-year, Receivables plummeted 92.6% in 2022 and then soared 824.04% in 2024.
  • Over 5 years, Receivables stood at $600.1 million in 2022, then decreased by 11.85% to $529.0 million in 2023, then soared by 824.04% to $4.9 billion in 2024, then rose by 2.92% to $5.0 billion in 2025, then rose by 7.02% to $5.4 billion in 2026.
  • The last three reported values for Receivables were $5.4 billion (Q1 2026), $5.0 billion (Q1 2025), and $4.9 billion (Q1 2024) per Business Quant data.